These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36916168)

  • 1. Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease - who and how?
    Teng ML; Tan DJH; Ng CH; Huang DQ
    Clin Mol Hepatol; 2023 Apr; 29(2):404-407. PubMed ID: 36916168
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease".
    Jamialahmadi O; Bianco C; Pelusi S; Romeo S; Valenti L
    J Hepatol; 2021 Jun; 74(6):1494-1496. PubMed ID: 33676949
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis.
    Tovo CV; de Mattos AZ; Coral GP; Sartori GDP; Nogueira LV; Both GT; Villela-Nogueira CA; de Mattos AA
    World J Gastroenterol; 2023 Jan; 29(2):343-356. PubMed ID: 36687125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey.
    Cotrim HP; Oliveira CP; Coelho HS; Alvares-da-Silva MR; Nabuco L; Parise ER; Ivantes C; Martinelli AL; Galizzi-Filho J; Carrilho FJ
    Clinics (Sao Paulo); 2016 May; 71(5):281-4. PubMed ID: 27276398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease: Definition and subtypes.
    Han SK; Baik SK; Kim MY
    Clin Mol Hepatol; 2023 Feb; 29(suppl):S5-S16. PubMed ID: 36577427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
    Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
    Marengo A; Rosso C; Bugianesi E
    Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Kanneganti M; Singal AG
    Gastroenterology; 2022 May; 162(6):1772-1774. PubMed ID: 35120916
    [No Abstract]   [Full Text] [Related]  

  • 11. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic factors affecting hepatocellular carcinoma in steatohepatitis.
    Zarrinpar A; Faltermeier CM; Agopian VG; Naini BV; Harlander-Locke MP; Kaldas FM; Farmer DG; Busuttil RW
    Liver Int; 2019 Mar; 39(3):531-539. PubMed ID: 30427105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Cernea S; Onișor D
    World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease.
    Long J; Bian J; Zhao H
    J Hepatol; 2021 Jun; 74(6):1493-1494. PubMed ID: 33476746
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical features and management issues of NAFLD-related HCC: what we know so far.
    Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?
    Edenvik P; Davidsdottir L; Oksanen A; Isaksson B; Hultcrantz R; Stål P
    Liver Int; 2015 Jul; 35(7):1862-71. PubMed ID: 25524812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States.
    Younossi ZM; Harring M; Younossi Y; Ong JP; Alqahtani SA; Stepanova M
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2915-2917.e1. PubMed ID: 34666156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.